Related Experiment Videos
Malignant hyperthermia and severe hypoglycemia after reexposure to halothane
T Bichel1, J L Canivet, P Damas
1Department of Anesthesiology, University Hospital of Liege, C.H.U. B 35, Domaine Universitaire du Sart Tilman, Belgium.
Acta Anaesthesiologica Belgica
|January 1, 1994
Summary
Malignant hyperthermia in a child was triggered by halothane reexposure, leading to severe hypoglycemia and liver issues. The exact cause of these complications is unclear, but halothane or dantrolene toxicity is suspected.
Area of Science:
- Anesthesiology
- Pediatric Medicine
- Toxicology
Background:
- Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder of skeletal muscle.
- Inhalational anesthetics like halothane are known triggers for MH episodes.
- Pediatric patients may present unique challenges in managing MH and its complications.
Observation:
- A four-year-old child experienced a malignant hyperthermia episode upon reexposure to halothane.
- The episode was marked by the sudden onset of severe hypoglycemia.
- Significant liver enzymatic disturbances were also noted during the clinical presentation.
Findings:
- The malignant hyperthermia episode was directly linked to halothane administration.
- Early and severe hypoglycemia was a prominent complication, suggesting a metabolic derangement.
- Elevated liver enzymes indicated hepatic injury, with potential contributions from anesthetic agents or treatments.
Implications:
- This case highlights the critical need for vigilance in pediatric anesthesia, especially with known MH susceptibility.
- The co-occurrence of hypoglycemia and liver dysfunction warrants further investigation into the pathophysiology of MH-related complications.
- Consideration of halothane and dantrolene as potential causes of hepatic toxicity in this context is crucial for future clinical management.